Indeed, pioneering studies showed therapeutic value for PPARγ agonists in CML patients and AML xenograft models, and BMA participated at least in the beneficial effects of these compounds against AML. Here, PPARG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.